Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
Boehringer Ingelheim and Click Therapeutics today announced they have entered into a collaboration for the development and commercialization of a prescription-based digital therapeutic. It will utilize cognitive and neurobehavioral mechanisms delivered through Click’s proprietary engagement platform with the goal of reducing cognitive deficits and impaired social functioning in patients with schizophrenia. Together the two companies will join their expertise to develop a novel mobile application, CT-155, which combines multiple clinically validated therapeutic interventions to help schizophrenia patients modify their behavior to achieve positive clinical outcomes alone and in combination with pharmaceutical therapy options. The partnership aims to provide better tools and resources to those living with schizophrenia, where there remains a huge unmet need due to lack of access to psychosocial intervention therapies.
“At Boehringer Ingelheim we believe that digital technologies can offer exciting new ways to help patients in need. Therefore, we are pleased to partner with Click Therapeutics on the advancement of a prescription-based digital therapeutic, which will hopefully provide better treatment for patients with schizophrenia,” said Jan Stefan Scheld, M.D., Corporate Senior Vice President, Therapeutic Area Head CNS, Retinopathies & Emerging Areas, Boehringer Ingelheim. “CT-155 is an excellent addition to our CNS pipeline portfolio; it reflects our patient centric approach and translates evidence showing how behavioral modification can induce positive neuronal changes into a widely accessible solution. Further it has the potential to be prescribed together with Boehringer Ingelheim’s schizophrenia pipeline compounds possibly enhancing the benefit of pharmacotherapy for patients,” added Cornelia Dorner-Ciossek, Ph.D., Director CNS Diseases Research at Boehringer Ingelheim.
Schizophrenia is one of the 15 leading causes of disability worldwide, with approximately half of all patients exhibiting co-occurring mental and/or behavioral health disorders.1 Schizophrenia is a serious mental health condition that alters a person’s perception of reality and impacts how they think, feel, and behave, and patients diagnosed with schizophrenia can remain functionally impaired due to insufficiently treated negative symptoms, including cognitive deficits and limited social functioning.2 Treatment guidelines recommend tailored psychosocial intervention therapies, however, access to these interventions is limited.2,3 Providing a novel, digital therapeutic option has the potential to significantly increase patient access to treatment and positively impact their quality of life.
“Partnering with Boehringer Ingelheim allows us to leverage their considerable experience in the clinical development and global commercialization of new treatment options for neuropsychiatric diseases to improve the efficacy and reach of our digital therapeutic software,” said David Benshoof Klein, CEO, Click Therapeutics. “We look forward to evaluating CT-155 in a pivotal clinical study, working together with Boehringer Ingelheim to achieve FDA and international regulatory authorization and to demonstrate the clinical efficacy of this prescription-based digital therapeutic software alone and in combination with traditional pharmaceutical treatments.”
Boehringer Ingelheim recognizes the importance of finding new solutions for people living with neuropsychiatric disorders. As part of its innovative CNS research program, Boehringer Ingelheim has developed and applied new ways to study the brain pathophysiology and to identify dysfunctions in the brain’s neuronal pathways that may be contributing to the symptoms of neuropsychiatric disorders. Combining digital innovations that are based on the principles of cognitive behavioral therapy with pharmacological solutions that also address symptoms at the root cause is key to making progress in clinical trials and improving the lives of patients with neuropsychiatric disorders. The partnership announced today provides both companies with the opportunity to further establish digital therapeutics as a meaningful new treatment category for patients and providers.
Under the terms of the partnership agreement, Click Therapeutics will be primarily responsible for research and development activities, and will support Boehringer Ingelheim as it undertakes worldwide commercialization activities.
Click Therapeutics will receive under the terms of the partnership agreement an upfront payment and funding for research and development activities as well as clinical, regulatory and commercial milestones representing a total deal value of over USD 500 million. Additionally, Click Therapeutics will receive tiered royalties on annual net sales of CT-155 worldwide.
Please click on the following link for ‘Notes to Editors’:
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
Senior Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
Chief of Staff
P: +1 423-362-0767
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GrAI Matter Labs Raises $14M to Bring Fastest AI per Watt to Every Device on the Edge23.11.2020 20:00:00 CET | Press release
GrAI Matter Labs, a pioneer of brain inspired ultra-low latency computing, today announced its latest financing round of $14 million. The round was led by iBionext, joined by all existing investors and newly welcomed Bpifrance through the Future Investment Program and Celeste Management. The company will utilize the funds to accelerate design and market launch of its first GrAI® full-stack AI system-on-chip platform, to deliver on customer needs at the edge. GrAI Matter Labs’ programmable NeuronFlow™ technology enables industry-leading inference latency efficiently – more than an order of magnitude better than competing solutions. Its current accelerator chip GrAI One and the GrAI One HDK are available for product evaluation and application programming. The upcoming GrAI® full-stack AI system-on-chip platform will drive a significant step in visual inference capabilities in robotics, industrial automation, AR/VR and surveillance products and markets. “Securing this funding round is a t
Von Gahlen Building Major Component of SHINE’s One-of-a-Kind Isotope Plant23.11.2020 20:00:00 CET | Press release
SHINE Medical Technologies LLC and Von Gahlen International Inc. today announced that Von Gahlen will build and install the “supercell,” a bank of 10 hot cells, for SHINE’s U.S. medical isotope production facility in Janesville, Wis. The supercell will house the key processes at the end of isotope production, including the extraction, purification and packaging of the molybdenum-99, or Mo-99, produced elsewhere in the plant. The hot cells allow for remote operation of the process equipment using specialized features, designed through close collaboration between SHINE and Von Gahlen engineers. Von Gahlen has its headquarters in the Netherlands and is a state-of-the-art manufacturer of shielding solutions for nuclear medicine and radiopharmacy. Von Gahlen was awarded the contract for the supercell based on this expertise, commitment to the project, and its alignment with SHINE’s core values. Fabrication of the hot cells is underway and delivery is expected in the second half of 2021. “We
Defense Innovation Unit (DIU) Selects Immervision InnovationLab to Develop a Computer Vision Wide Angle Camera for the Blue UAS Framework Project23.11.2020 17:01:00 CET | Press release
Immervision, the Montreal-based leader in wide-angle intelligent vision, today announced it has received an award from the Defense Innovation Unit (DIU), part of the U.S. Department of Defense (DoD) for a Blue UAS Frameworkeffort. The Immervision InnovationLab team is developing a wide-angle computer vision camera for small Unmanned Aerial Systems (sUAS), enabling advanced low-light vision for Blue UAS Frameworkeffort which provides affordable, trusted, high performing, and interoperable UAS drone technologies for commercial and defense applications. “We are honored that the Defense Innovation Unit has chosen Immervision’s InnovationLab to create this innovative wide angle computer vision camera optimized for drones in low light vision and autonomous flight,” said Alessandro Gasparini, Executive Vice President, Operations and Chief Commercial Officer of Immervision. “Immervision’s technology has been widely adopted in aerospace, surveillance systems and for consumer electronics for ove
GlobalLogic Acquires ECS Group, a Leading UK-Based Digital Transformation Company23.11.2020 15:00:00 CET | Press release
GlobalLogic Inc., a leader in Digital Product Engineering, today announced that it has acquired ECS Group, a leading digital transformation and DevOps consultancy. Headquartered in London, ECS delivers digital solutions that harness the latest cloud technologies, with a focus on Digital Engineering, Data Analytics and Customer Experience. The company serves multiple industries, with particular expertise in the banking and financial services sector. With the acquisition of ECS, GlobalLogic advances its European strategy, expands its Financial Services footprint and adds a host of complementary cloud-centric offerings to its portfolio. ECS brings to GlobalLogic a highly regarded proficiency in cloud architecture and advisory services as well as expertise in leading cloud platforms. Notably, ECS possesses rich Amazon Web Services (AWS) capabilities, for which ECS is an Advanced Consulting Partner and Amazon Connect Service Delivery Partner. Additionally, ECS holds the DevOps Competency Ac
Hisense Sued for Infringement of AVC Essential Patents23.11.2020 15:00:00 CET | Press release
MPEG LA announced today that patent owners in MPEG LA’s AVC Patent Portfolio License have filed patent enforcement actions in the Landgericht Düsseldorf, Germany against Hisense Germany GmbH ("Hisense") for infringing patents essential to the AVC/H.264 (MPEG-4 Part 10) digital video coding standard used in mobile devices, televisions and other products. According to the complaints, Hisense offers television products in Germany, which use patent protected AVC methods without licenses with the individual patent holders or a portfolio license that includes these patents offered by MPEG LA. The suits seek monetary damages and injunctions. The plaintiffs are represented by a team led by Axel Verhauwen of Krieger Mes & Graf v. der Groeben and Gottfried Schüll of Cohausz & Florack. MPEG LA, LLC MPEG LA is the world’s leading provider of one-stop licenses for standards and other technology platforms. Starting in the 1990s, it pioneered the modern-day patent pool helping to produce the most wid
Patient Safety Movement Foundation Launches New Commitment Model Supporting Mission to Achieve Zero Preventable Patient Deaths By 203023.11.2020 14:00:00 CET | Press release
Every year, more than 4.8 million patients lose their lives to preventable medical errors worldwide. The Patient Safety Movement Foundation (PSMF), a global non-profit, is committed to achieving zero preventable patient deaths by 2030 and has launched a revised commitment model for hospitals and healthcare organizations to help make its goal a reality. The Patient Safety Movement Foundation’s initial model focused on securing healthcare organization commitments to target the leading causes of preventable harm and death occurring in healthcare facilities. Today’s updates instead ask organizations to commit to building and sustaining a foundation for safe and reliable care – and provide free “Actionable Patient Safety Solutions” (APSS), which include evidence-based best practice summaries and solutions, educational resources and virtual coaching to help organizations integrate these best practices into their existing processes. “Under our previous commitment model, our hospital and healt